DE Burlo Group Inc. Lowers Stock Position in Masimo Co. (NASDAQ:MASI)

DE Burlo Group Inc. cut its position in shares of Masimo Co. (NASDAQ:MASI) by 11.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 8,752 shares of the medical equipment provider’s stock after selling 1,100 shares during the period. DE Burlo Group Inc.’s holdings in Masimo were worth $1,167,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Edgestream Partners L.P. acquired a new stake in shares of Masimo in the second quarter valued at about $645,000. Simplify Asset Management Inc. increased its position in shares of Masimo by 120.4% during the second quarter. Simplify Asset Management Inc. now owns 21,670 shares of the medical equipment provider’s stock valued at $2,729,000 after acquiring an additional 11,838 shares during the last quarter. ING Groep NV boosted its stake in shares of Masimo by 143.3% in the third quarter. ING Groep NV now owns 240,900 shares of the medical equipment provider’s stock valued at $32,119,000 after purchasing an additional 141,900 shares during the period. Advisors Asset Management Inc. boosted its stake in shares of Masimo by 32.1% in the first quarter. Advisors Asset Management Inc. now owns 9,009 shares of the medical equipment provider’s stock valued at $1,323,000 after purchasing an additional 2,187 shares during the period. Finally, Thrivent Financial for Lutherans boosted its stake in shares of Masimo by 42.1% in the second quarter. Thrivent Financial for Lutherans now owns 1,217,357 shares of the medical equipment provider’s stock valued at $153,314,000 after purchasing an additional 360,497 shares during the period. 85.96% of the stock is owned by hedge funds and other institutional investors.

Masimo Price Performance

NASDAQ:MASI opened at $164.95 on Thursday. The firm has a market cap of $8.83 billion, a price-to-earnings ratio of 113.76 and a beta of 0.97. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. The company’s 50-day moving average is $141.16 and its two-hundred day moving average is $127.47. Masimo Co. has a 12-month low of $91.60 and a 12-month high of $173.90.

Masimo (NASDAQ:MASI) last posted its quarterly earnings data on Tuesday, November 5th. The medical equipment provider reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.84 by $0.14. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The company had revenue of $504.60 million during the quarter, compared to the consensus estimate of $502.87 million. During the same quarter in the prior year, the company posted $0.63 EPS. The company’s quarterly revenue was up 5.4% compared to the same quarter last year. Research analysts expect that Masimo Co. will post 4.04 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. BTIG Research lifted their price target on shares of Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Wells Fargo & Company boosted their price objective on shares of Masimo from $160.00 to $171.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 6th. Raymond James raised shares of Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 target price on the stock in a report on Wednesday, November 6th. Piper Sandler boosted their price objective on shares of Masimo from $165.00 to $180.00 and gave the company an “overweight” rating in a research note on Wednesday, November 6th. Finally, Needham & Company LLC restated a “hold” rating on shares of Masimo in a research report on Wednesday, November 6th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $163.67.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.